Orchestra BioMed Holdings Inc (OBIO) USD0.0001

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.